CVAC (CureVac NV) EBIT per Share : $0.97 (TTM As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is CureVac NV EBIT per Share?

CureVac NV's EBIT per Share for the three months ended in Dec. 2024 was $-0.18. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $0.97.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for CureVac NV's EBIT per Share or its related term are showing as below:

During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of CureVac NV was -10.20% per year. The lowest was -74.50% per year. And the median was -30.60% per year.

CVAC's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 7.9
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

CureVac NV's EBIT for the three months ended in Dec. 2024 was $-41.0 Mil.

CureVac NV EBIT per Share Historical Data

The historical data trend for CureVac NV's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV EBIT per Share Chart

CureVac NV Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT per Share

Get a 7-Day Free Trial

-0.99

-2.44

-1.38

-1.28

0.89

CureVac NV Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EBIT per Share	Get a 7-Day Free Trial															-0.42	-0.34	-0.34	1.83	-0.18

CureVac NV EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

CureVac NV's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as

	EBIT per Share		(A: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	199.875	/	225.270
=	0.89

CureVac NV's EBIT per Share for the quarter that ended in Dec. 2024 is calculated as

	EBIT per Share		(Q: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-41.044	/	224.940
=	-0.18

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.97

CureVac NV (NAS:CVAC) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

CureVac NV EBIT per Share Related Terms

Thank you for viewing the detailed overview of CureVac NV's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

CureVac NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (NAS:CVAC) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

1CVAC:Italy 0A9E:UK 5CV:Germany 5CV:Germany 5CV:Germany 5CV:Germany CVAC:Austria

Address

Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076

Website

https://www.curevac.com

CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.